{"schema_version":"secwatch.filing_event.v1","accession":"0001485003-23-000010","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2023-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.196557+00:00","generated_at":"2026-06-20T06:35:07.493423+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sesen Bio receives Nasdaq delisting notice; warns of dissolution if merger fails","bullets":["Nasdaq notified Sesen on Jan 25, 2023 of non-compliance with $1.00 bid price; delisting unless hearing requested.","Company plans to request Nasdaq Hearings Panel hearing to stay delisting and remain listed pending decision.","Without pending merger with Carisma, likely path is delisting, SEC deregistration, and court-managed dissolution and liquidation.","In dissolution, only 60%-90% of ~$140M cash (~$0.40-$0.60/share) available for initial distribution, taking 6+ months.","Board unanimously recommends merger vote at Special Meeting on March 2, 2023; seeking reverse stock split approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001485003-23-000010","json":"https://secwatch.observer/filing/0001485003-23-000010.json","markdown":"https://secwatch.observer/filing/0001485003-23-000010.md","text":"https://secwatch.observer/filing/0001485003-23-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000010/0001485003-23-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000010/sesn-20230125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T06:35:07.493423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40612ebfdeee7b8e82b7b06518e965196161f700","claim":"Carisma Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"January 25, 2023 notification to the Company by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”), the Company’s common stock, par value $0.001 (the “Common Stock”), will be delisted from Nasdaq unless the Company requests a hearing before a Nasdaq Hearings Panel (the “Panel”). A copy of the press release is attached as Exhibit 99.1 hereto and incorporated he","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000010/0001485003-23-000010-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}